Search Results - Metabolic disorders




4 Results Sort By:
Topical treatment with TGFbeta3 to facilitate skin and corneal wound healing in diabetic patients
Topical Treatment with TGFb3 to Facilitate Skin and Corneal Wound Healing in Diabetic Patients WSU Tech#: 14-1207 Technology Summary: TGFb3 has been implicated in the reduction of scar formation in wound healing. Renovo Group PLC, is a European based biopharmaceutical company developing drugs to reduce scaring, improve wound healing and enhance...
Published: 2/10/2017   |   Inventor(s): Fu-Shin Yu
Keywords(s):  
Category(s): Medical, Biologicals, Biomedical, Drug Discovery, Metabolic disorders, Protein/peptides, Therapeutics, Life Science
Dual action nanocarrier combining CXCR4 antagonist and polyplex gene delivery for treatment of metastatic cancer and other diseases
Novel bio-reducible polymer compositions which combine the ability to act as a CXCR4 antagonist and simultaneously provide enhanced gene delivery through the formation of inert nanocarrier polyplexes have been developed. As would be expected for biodegradable polymers, the cytotoxicity of these nanocarrier compositions are very low with measured IC...
Published: 9/10/2012   |   Inventor(s): David Oupicky, Jing Li
Keywords(s): Cancer, Cancer Therapies, Compound, Drug Delivery, Drug Target, Formulation, Imaging, Nanomaterials, Pharmaceuticals, Therapeutics
Category(s): Drug Delivery, Gene Therapy, Therapeutics, Life Science, Oncology, Nano-based, Metabolic disorders, Biologicals
Novel Mammalian Putative Phosphatidylinositol-4-Phosphate-5-Kinase
This invention is a novel mammalian gene involved in membrane trafficking, more specifically, insulin‑induced translocation of the fat/muscle-specific glucose transporter GLUT4. Background & Unmet Need: Both Type I (Juvenile onset) and Type II (Maturity onset) Diabetes Mellitus result in a profound state of high glucose in the circulatio...
Published: 5/18/2010   |   Inventor(s): Assia Shisheva
Keywords(s): DNA, Drug Target, Therapeutics
Category(s): Diseases, Life Science, Metabolic disorders, Therapeutics, Biologicals
DNA Molecule Encoding the B3 Adrenegic Receptor
This technology describes the correct protein sequence of the β3 receptor to aid in the development of adult-onset diabetes drugs. Background & Unmet Need: The β3 receptor is currently being developed as a therapeutic target for human obesity and adult onset diabetes mellitus by several pharmaceutical companies. In order to develop...
Published: 5/18/2010   |   Inventor(s): James Granneman, Kristine Lahners, Donald Rao
Keywords(s): Diabetes, Disease, DNA, Drug Target, Obesity, Therapeutics
Category(s): Life Science, Metabolic disorders, Diagnostics, Research tools, Receptors/targets